



Supplemental Figure 1. BRD4 inhibitors suppress the proliferation of prostate cancer and lymphoma models. Cell number was determined as described in the Materials and Methods section.



Supplemental Figure 2. Real time PCR data showing relative changes in MYC and TFRC levels post treatment with bioactive doses of BRD4 inhibitors in the A549 cell line. As expected, no changes in MYC or TFRC mRNA levels were observed.



Supplemental Figure 3. A. Representative coronal and transverse microPET images of mice bearing TDM8 subcutaneous tumors in the right flank, and injected with  $^{89}\text{Zr}$ -transferrin. Persistent and high uptake of the radiotracer is observed after 4 hours. Region of interest analysis shows the uptake of  $^{89}\text{Zr}$ -transferrin in tumors over time. The time activity curve corroborates the pharmacokinetics previously observed for  $^{89}\text{Zr}$ -transferrin in mice. C. Biodistribution from selected tissues showing that the accumulation of  $^{89}\text{Zr}$ -transferrin in TDM8 tumors (48 hours post injection) exceeds the activity in blood and muscle.

